Previous 10 | Next 10 |
Histogen ( HSTO ) +78% . Canoo ( GOEV ) +74% after signing a deal with Walmart for 4,500 all electric delivery vehicles. Novo Integrated Sciences ( NVOS ) +14% expects to report over fivefold increase in Q3 revenue. Annexon ( ANNX ) +13% p...
Greenwich LifeSciences ( NASDAQ: GLSI ) said the U.S. Food and Drug Administration (FDA) removed a clinical hold on a phase 3 trial in breast cancer allowing it to progress. The trial, dubbed Flamingo-01 , will evaluate a combination of immunotherapy GP2 + GM-...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical...
Greenwich LifeSciences ( NASDAQ: GLSI ) said Monday it suspended its share repurchase program. GLSI repurchased ~520K shares for ~$7.5M under the program, which had been resumed in May . The firm had ~12.8M shares outstanding following the buybacks. For furth...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program. Under...
The stock market has been under unimaginable selling pressure for the last several quarters. The stock market sell-off has been exasperated by the Fed's actions to reduce inflation. This lays out a vast buying opportunity that only the most skilled investors/traders will take adva...
Greenwich LifeSciences (NASDAQ:GLSI) plans to resume its existing stock repurchase program; ~$4.5M remained available under the current program. As of March 31, 2022, the company had 12.95M shares of common stock outstanding. For further details see: Greenwich LifeSciences to resume sto...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program. Under the repurchase program previously authorized by ...
FDA review of manufacturing plans and pharmacy procedures associated with a recently placed clinical hold on the FLAMINGO-01 phase III clinical trial is underway with formal feedback from the FDA expected shortly. Greenwich is prepared to address FDA manufacturing and pharmacy procedu...
Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was...
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
2024-04-02 01:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their conf...